FoundationOne Liquid extends the benefits of comprehensive genomic profiling to more clinical situations with a single blood draw.Use FoundationOne CDx where tissue is available. When tissue biopsy is not feasible, there is insufficient tissue for analysis and/or when disease progression is suspected, try FoundationOne Liquid.1,2
Genes and biomarkers
Analyses 70 genes and reports MSI-High status
FoundationOne Liquid leverages the comprehensive genomic profiling approach and, in a single test, detects the four main classes of genomic alterations in 70 genes and reports MSI-High status.1 High specificity and sensitivity ensure you can be confident in the alterations reported.1
Cancer patients’ blood contains circulating cell-free DNA (cfDNA) released from healthy tissue and also tumour tissue (ctDNA). This DNA is highly fragmented, in very low amounts and varies between tumour type and patients. FoundationOne Liquid utilises enhanced ctDNA extraction to accurately identify unique ctDNA fragments from a single blood draw.
Supports clinical decision-making
A clear, in-depth report provides insights on your patient’s genomic profile as well as associated targeted therapies, immunotherapies and relevant clinical trials. The report incorporates results from prior Foundation Medicine services to provide an integrated view of tumour evolution.4